articleMMWR Morbidity and Mortality Weekly ReportJul 20, 2023DIAMOND OA

Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023

MMMichael MelgarABAmadea BrittonLELauren E. RoperHKH. Keipp TalbotSSSarah S. Long
PubMed
Indexed incrossrefpubmed

Abstract

Respiratory syncytial virus (RSV) is a cause of severe respiratory illness in older adults. In May 2023, the Food and Drug Administration approved the first vaccines for prevention of RSV-associated lower respiratory tract disease in adults aged ≥60 years. Since May 2022, the Advisory Committee on Immunization Practices (ACIP) Respiratory Syncytial Virus Vaccines Adult Work Group met at least monthly to review available evidence regarding the safety, immunogenicity, and efficacy of these vaccines among adults aged ≥60 years. On June 21, 2023, ACIP voted to recommend that adults aged ≥60 years may receive a single dose of an RSV vaccine, using shared clinical decision-making. This report summarizes the body of…

Citation impact

311
total citations
FWCI
63.41
Percentile
100%
References
21
Citations per year

Authors

7

Topics & keywords

Topics
Keywords
  • Medicine
  • Advisory committee
  • Immunization
  • Immunogenicity
  • Respiratory tract infections
  • Lower respiratory tract infection
  • Vaccination
  • Intensive care medicine
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding